---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001565"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2024-09-11T23:59:59+00:00"
generated_at: "2026-05-31T05:24:06.189299+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lipella shareholders approve reverse stock split authorization at annual meeting

## Summary
- All seven director nominees elected (including CEO Jonathan Kaufman); broker non-votes of 1,703,278.
- Reverse stock split authorized (3,881,533 for, 407,381 against); board may implement up to 1:150 within one year.
- Ratification of auditor Urish Popeck & Co. for FY2024 ratified with 4,232,289 votes for.

## SEC filing metadata
- accession: 0001753926-24-001565
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2024-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392624001565/0001753926-24-001565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392624001565/g084428_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001565
- JSON: https://secwatch.observer/filing/0001753926-24-001565.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.